CO6140057A2 - Nuevos compuestos cristalinos - Google Patents
Nuevos compuestos cristalinosInfo
- Publication number
- CO6140057A2 CO6140057A2 CO08108825A CO08108825A CO6140057A2 CO 6140057 A2 CO6140057 A2 CO 6140057A2 CO 08108825 A CO08108825 A CO 08108825A CO 08108825 A CO08108825 A CO 08108825A CO 6140057 A2 CO6140057 A2 CO 6140057A2
- Authority
- CO
- Colombia
- Prior art keywords
- acid
- naphthalene
- tartaric
- acids
- crystal compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
1.- Compuestos cristalinos A de la fórmula general I, en la que A1 significa Br, -CH3, -CF3 o -C2H5, A2 significa -NH2, -OH o -C2H5, A3 significa Br, CI, -CH3 o H, X significa -CH2-, -NH- o -O-, Y1 significa N o CH, Y2 significa N o CH e Y3 significa -CH2-, N(CH3) o -O-, y que se presentan en forma de sus sales con ácidos, fisiológicamente tolerables, habiéndose seleccionado los ácidos a partir del grupo B constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido fosfórico, ácido bencenosulfónico, ácido p-toluenosulfónico, ácido maleico, ácido succínico, ácido fumárico, ácido D-(-)-tartárico, ácido L-(+)-tartárico, ácido naftalin-2-sulfónico y ácido naftalin-1,5-disulfónico, así como los polimorfos, los correspondientes solvatos e hidratos. 2.- Compuestos cristalinos A de la fórmula general I según la reivindicación 1, que se han seleccionado del grupo constituido por y que se presentan en forma de sus sales fisiológicamente tolerables con ácidos B, seleccionados a partir de ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido fosfórico, ácido bencenosulfónico, ácido p-toluenosulfónico, ácido maleico, ácido succínico, ácido fumárico, ácido D-(-)-tartárico, ácido L-(+)-tartárico, ácido naftalin-2-sulfónico y ácido naftalin-1,5-disulfónico, así como los polimorfos, los correspondientes solvatos e hidratos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006017827A DE102006017827A1 (de) | 2006-04-13 | 2006-04-13 | Neue kristalline Verbindungen |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6140057A2 true CO6140057A2 (es) | 2010-03-19 |
Family
ID=38514672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO08108825A CO6140057A2 (es) | 2006-04-13 | 2008-10-10 | Nuevos compuestos cristalinos |
Country Status (20)
Country | Link |
---|---|
US (1) | US7638625B2 (es) |
EP (1) | EP2010513A2 (es) |
JP (1) | JP2009533387A (es) |
KR (1) | KR20090007428A (es) |
CN (1) | CN101421263A (es) |
AR (1) | AR060442A1 (es) |
AU (1) | AU2007239505A1 (es) |
BR (1) | BRPI0710151A2 (es) |
CA (1) | CA2648140A1 (es) |
CO (1) | CO6140057A2 (es) |
DE (1) | DE102006017827A1 (es) |
EA (1) | EA200802049A1 (es) |
EC (1) | ECSP088737A (es) |
MX (1) | MX2008013158A (es) |
NO (1) | NO20083709L (es) |
PE (1) | PE20080735A1 (es) |
TW (1) | TW200808767A (es) |
UY (1) | UY30280A1 (es) |
WO (1) | WO2007118819A2 (es) |
ZA (1) | ZA200806859B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7491717B2 (en) * | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
BRPI0712492A2 (pt) * | 2006-06-08 | 2012-08-21 | Boehringer Ingelheim Int | uso de antagonistas de cgpr e composição farmacêutica compreendendo antagonistas de cgpr. |
RS56556B1 (sr) * | 2012-02-27 | 2018-02-28 | Bristol Myers Squibb Co | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199900537T2 (xx) | 1996-09-10 | 1999-07-21 | Dr. Karl Thomae Gmbh | D�n��t�r�lm�� amino asitler, bunlar� i�eren farmas�tik preparatlar. |
DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10250080A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
-
2006
- 2006-04-13 DE DE102006017827A patent/DE102006017827A1/de not_active Withdrawn
-
2007
- 2007-04-11 JP JP2009504732A patent/JP2009533387A/ja active Pending
- 2007-04-11 MX MX2008013158A patent/MX2008013158A/es active IP Right Grant
- 2007-04-11 PE PE2007000446A patent/PE20080735A1/es not_active Application Discontinuation
- 2007-04-11 EP EP07727956A patent/EP2010513A2/de not_active Ceased
- 2007-04-11 CN CNA200780012808XA patent/CN101421263A/zh active Pending
- 2007-04-11 WO PCT/EP2007/053488 patent/WO2007118819A2/de active Application Filing
- 2007-04-11 BR BRPI0710151-1A patent/BRPI0710151A2/pt not_active IP Right Cessation
- 2007-04-11 EA EA200802049A patent/EA200802049A1/ru unknown
- 2007-04-11 KR KR1020087027714A patent/KR20090007428A/ko not_active Application Discontinuation
- 2007-04-11 CA CA002648140A patent/CA2648140A1/en not_active Abandoned
- 2007-04-11 AU AU2007239505A patent/AU2007239505A1/en not_active Abandoned
- 2007-04-12 TW TW096112795A patent/TW200808767A/zh unknown
- 2007-04-12 UY UY30280A patent/UY30280A1/es not_active Application Discontinuation
- 2007-04-12 US US11/734,520 patent/US7638625B2/en active Active
- 2007-04-13 AR ARP070101573A patent/AR060442A1/es unknown
-
2008
- 2008-08-08 ZA ZA200806859A patent/ZA200806859B/xx unknown
- 2008-08-28 NO NO20083709A patent/NO20083709L/no not_active Application Discontinuation
- 2008-09-15 EC EC2008008737A patent/ECSP088737A/es unknown
- 2008-10-10 CO CO08108825A patent/CO6140057A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007118819A3 (de) | 2008-05-29 |
AR060442A1 (es) | 2008-06-18 |
AU2007239505A1 (en) | 2007-10-25 |
CA2648140A1 (en) | 2007-10-25 |
MX2008013158A (es) | 2008-10-22 |
EP2010513A2 (de) | 2009-01-07 |
JP2009533387A (ja) | 2009-09-17 |
PE20080735A1 (es) | 2008-07-25 |
UY30280A1 (es) | 2007-11-30 |
BRPI0710151A2 (pt) | 2011-08-02 |
ECSP088737A (es) | 2008-10-31 |
NO20083709L (no) | 2008-10-31 |
US7638625B2 (en) | 2009-12-29 |
CN101421263A (zh) | 2009-04-29 |
TW200808767A (en) | 2008-02-16 |
WO2007118819A2 (de) | 2007-10-25 |
DE102006017827A1 (de) | 2007-10-18 |
US20080086003A1 (en) | 2008-04-10 |
EA200802049A1 (ru) | 2009-04-28 |
ZA200806859B (en) | 2009-08-26 |
KR20090007428A (ko) | 2009-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR7691A (es) | Nuevo procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
BR112012012584A2 (pt) | "processo para preparar sais de 4,5-diidroisoxazol-3-tiocarboxamidina 5,5-dissubstituídos de fórmula (i)" | |
EA201101089A1 (ru) | Производные оксадиазола в качестве агонистов рецептора s1p1 | |
CR20110013A (es) | Derivados de Heteroarilo como Inhibidores de DGAT1 | |
EA201200537A1 (ru) | Способ получения глюкопиранозил-замещенных производных бензилбензола | |
BR112012032244A2 (pt) | processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes | |
BRPI0905147A8 (pt) | processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável | |
ECSP10010405A (es) | Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico | |
EA200971100A1 (ru) | Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1) | |
AR075227A1 (es) | Procedimiento de sintesis de ivabradina y sus sales de adicion de acidos farmaceuticamente aceptables. | |
CR10671A (es) | Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas | |
MX2012002890A (es) | Polisiloxanos nuevos teniendo grupos de amonio cuaternarios y uso de estos. | |
DK1824479T3 (da) | Phenylpiperazin-derivater med en kombination af delvis dopamin-D2-receptoragonisme og serotonin-genoptagelsesinhibering | |
CL2010001639A1 (es) | Proceso para preparacion del hemitartrato de [5-(4,6-dimetil-1h-benzoimidazol-2-il-metil-pirimidin-2-il]-[3-(metil-piperidin-4-il)propil]amina; proceso de recristalizacion del hemitartrato; y hemitaatrato cristalino de [5-(4,6-dimetil-1h-benzoimidazol-2-il)-4-metil- pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina. | |
CL2009001414A1 (es) | Procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-benzazepin-2-ona sin aislacion de compuestos intermediarios; util para la sintesis de ivabradina. | |
CO6140057A2 (es) | Nuevos compuestos cristalinos | |
EA201200282A1 (ru) | Региоселективное получение производных 2-амино-5-трифторметилпиримидина | |
EA200870038A1 (ru) | Способ получения аминов | |
EA201270421A1 (ru) | 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт | |
CO6341560A2 (es) | Proceso para la preparacion de derivados de pirimidina sustituidos. | |
AR078179A1 (es) | Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable | |
ECSP077167A (es) | Nuevos compuestos heterociclicos | |
MX2012000685A (es) | Compuesto de 3-fenoximetilpirrolidina. | |
AR053410A1 (es) | Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios | |
CL2010000254A1 (es) | Procedimiento de sintesis de ivabradina por formacion de una imina; y los compuestos intermediarios considerados en el procedimiento. |